Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Neutral 0

Major health insurers show signs of recovery – but a key test looms

AI-generated analysis

📈 Major health insurers including UnitedHealth, Elevance, Cigna, and Humana reported solid first-quarter earnings that beat analyst estimates.

💼 Investor sentiment improved following these positive reports, with some companies also raising their long-term 2026 outlooks.

⚠️ Analysts caution that Q1 results are preliminary because of significant time lags in processing medical claims for full cost data.

📉 Insurers strengthened medical reserves, creating a financial cushion that supports their current positive earnings outlooks.

❄️ Some of the strong Q1 performance is attributed to seasonal factors like a milder flu season and weather disruptions suppressing costs.

💰 Industry-wide cost controls have helped lower medical loss ratios, a key metric showing costs as a share of premiums.

🏥 Companies are actively exiting less profitable markets and shrinking membership to better align with rising medical expenses.

🚫 UnitedHealth announced it will stop offering Medicare Advantage plans in 109 U.S. counties starting in 2026.

📊 Commercial coverage saw higher premiums offset rising costs, while Medicaid results remain surprisingly solid despite enrollment declines.

⏳ The second quarter is viewed as the real proving ground when delayed claims from Q1 finally crystallize into full data.

🎯 Analysts warn that clearing the "underwriting hurdle" in Q2 is essential for validating pricing and predicting positive 2026 earnings.

🔮 Humana faces specific scrutiny after planning 25% Medicare Advantage membership growth for 2026 while keeping benefits stable.

😰 Investors are concerned about a potential repeat of CVS Health's Q2 2024 results, where costs missed targets despite membership growth.

🏛️ The Affordable Care Act marketplace remains a critical area to watch for insurers like Centene, Molina, and Elevance in Q2.

📋 The upcoming Wakely analysis in late June will be key for determining if revenue assumptions match actual member health risks.

📉 Even minor shifts in enrollment or member health profiles could lead to significant earnings gains or losses for these insurers.

Bullish Signals
  • Major health insurers including UnitedHealth, Elevance, Cigna, and Humana all beat first-quarter analyst estimates, boosting investor sentiment.
  • Insurers have strengthened their medical reserves, adding a financial cushion that could support their outlooks for the remainder of the year.
  • Medical loss ratios came in lower than expected for several companies, indicating improved cost controls and efficiency in segments like commercial coverage, Medicare, and Medicaid.
  • UnitedHealth plans to exit less profitable Medicare Advantage markets starting in 2026, a strategic move that helps align pricing with rising medical expenses.
  • Humana expects to grow its Medicare Advantage membership by 25% in 2026 while maintaining stable benefits, similar to the successful pattern seen at CVS Health in 2024.
  • Improvements in cost controls and stabilizing medical costs have contributed to surprisingly solid results in Medicaid, even as states tighten eligibility.
  • The sector is benefiting from a milder flu season and weather disruptions that temporarily suppressed medical costs, providing a positive start to the year.
Risk Factors
  • Insurers reported solid Q1 results based on estimates and incomplete claims data due to a lag in processing hospital stays and procedures that take one to two months to review.
  • Second quarter will serve as the real test where delayed claims crystallize, potentially revealing whether medical costs are tracking lower than expected.
  • Analysts warn investors to take first-quarter earnings 'with a grain of salt' because current performance relies on estimates rather than real hard claims data.
  • Humana faces specific concerns after CVS Health repeated a pattern in 2024 where it grew Medicare Advantage membership but later missed medical loss ratio targets significantly due to higher-than-expected costs.
  • The industry is vulnerable if recent improvements driven by conservative pricing and market exits do not hold up when complete second-quarter data becomes available.
  • Even small shifts in enrollment or member health profiles could lead to meaningful earnings losses as revealed in the Wakely analysis released in late June.
  • Investors will be forced to rely on estimates for first-quarter results while waiting for clearer read on underlying cost trends that only come with more claims data in Q2.
Full Analysis
Major health insurers such as UnitedHealth, Elevance, Cigna, and Humana reported solid first-quarter earnings that exceeded analyst expectations, driven by seasonal factors like a milder flu season and weather-related disruptions to medical spending. These results have improved investor sentiment, with several companies raising their outlooks for 2026, though analysts emphasize that the true test of underlying performance has not yet arrived due to significant lags in claims processing. Baird analyst Michael Ha noted that while first-quarter numbers appear strong due to conservative pricing and lower-than-expected medical loss ratios, actual hard data on claims typically lags by one to two months, meaning Q2 will serve as the critical proving ground for whether costs are truly under control or merely temporarily suppressed. Barclays analyst Andrew Mok added that the first-quarter beats were supported by strength across all major segments, including commercial coverage and Medicaid, but warned that investors must wait for more complete claims data in the second quarter to accurately assess if pricing strategies remain appropriate. A specific concern for Humana involves its aggressive growth plans for Medicare Advantage membership in 2026; Ha cautioned that similar growth by CVS Health in Q2 2024 was followed by missing medical loss ratio targets as costs eventually crystallized, suggesting investors should watch for repeating patterns where initial optimism gives way to cost pressures later in the year. The broader context includes strategic shifts within the industry where insurers have exited less profitable markets and adjusted benefits to align with rising expenses, such as UnitedHealth discontinuing Medicare Advantage plans in 109 counties effective 2026. While these actions have created a pricing cushion that helped Q1 results, the sector remains vulnerable to small shifts in enrollment or member health profiles under the Affordable Care Act marketplace, which could significantly impact earnings as June brings more clarity through data like the Wakely analysis. Ultimately, the second quarter will determine whether the 2026 growth targets are sustainable or if the industry faces a significant underwriting hurdle that could alter year-end earnings projections.